-
Mashup Score: 1COVID-19 Could Accelerate US Biosimilar Uptake - 4 year(s) ago
Although the coronavirus disease 2019 (COVID-19) pandemic has put a burden on the economy and the healthcare system in particular, Kashyap Patel, MD, believes that the crisis will likely speed up biosimilar uptake in the United States.
Source: Center for BiosimilarsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Ruby Singh Previews the AMCP eLearning Days Virtual Meeting - 4 year(s) ago
Ruby Singh, vice president for Education and Training, Academy of Managed Care Pharmacy (AMCP), speaks with Mary Caffrey about the upcoming AMCP eLearning Days, a virtual meeting that will take place April 20 to 24. AMCP’s annual meeting was cancelled due to coronavirus disease 2019 (COVID-19). This transcript is edited slightly for clarity.
Source: Center for BiosimilarsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Ruby Singh previews the #AMCP eLearning Days, coming Apr 20-24. https://t.co/c5IGqd40gt
-
-
Mashup Score: 0Mylan and Biocon Launch Pegfilgrastim Biosimilar in Australia - 4 year(s) ago
With the launch of Mylan and Biocon’s pegfilgrastim biosimilar, Australia adds another biosimilar to its portfolio of biosimilars in circulation.
Source: Center for BiosimilarsCategories: Hem/Onc News and JournalsTweet-
#Mylan and #Biocon launch pegfilgrastim biosimilar in Australia https://t.co/7d7onydpdX
-
-
Mashup Score: 0NCCN Guidelines May Aid US Biosimilar Uptake - 4 year(s) ago
The National Comprehensive Cancer Network (NCCN) Guidelines may help get biosimilars into circulation because the NCCN will recommend them for off-label uses.
Source: Center for BiosimilarsCategories: Hem/Onc News and JournalsTweet-
#NCCN guidelines may aid US #biosimilar uptake #Granix #neutropenia https://t.co/s7pQoIuwik
-
-
Mashup Score: 1Henlius' Denosumab Biosimilar Application Is Accepted by NMPA - 4 year(s) ago
China’s National Medical Products Administration (NMPA) has accepted Henlius Biotech’s new drug application for its denosumab biosimilar, hlx14.
Source: Center for BiosimilarsCategories: Hem/Onc News and JournalsTweet-
RT @IBCResearch: @OncoAlert "Henlius' Denosumab biosimilar application accepted by NMPA" #BCSM https://t.co/3reg6PrxbW
-
-
Mashup Score: 0Ontruzant Trastuzumab 420-mg Multidose Vial Approved by FDA - 4 year(s) ago
The FDA has approved a multidose vial of Samsung Bioepis’ trastuzumab biosimilar Ontruzant, which was first approved as a 150-mg single-dose vial in January 2019 and has yet to reach the US market in either form.
Source: Center for BiosimilarsCategories: General Medicine Journals and SocietiesTweet-
New multidose vial of #Ontruzant #trastuzumab #biosimilar OK'd by @US_FDA https://t.co/GVfzfkzpTS
-
-
Mashup Score: 0FDA Officials Predict More Insulins Under New Biologics Pathway - 4 year(s) ago
Competition in the insulin market is expected to rise because insulin products will be approved under the regulatory pathway for biological products now that the transition period added to the Biologics Price Competition and Innovation Act (BPCIA) of 2009 has officially ended, the FDA said.
Source: Center for BiosimilarsCategories: General Medicine Journals and SocietiesTweet-
Today, the @US_FDA predicts more #insulins under the new #biologics pathway #NewRule https://t.co/iMAgt4pePF
-
-
Mashup Score: 1Teva, Celltrion Launch Fourth Trastuzumab Biosimilar - 4 year(s) ago
Teva Pharmaceuticals USA and Celltrion Healthcare have launched the fourth trastuzumab biosimilar, Herzuma, at a 10% discount to the cost of reference product Herceptin.
Source: Center for BiosimilarsCategories: Hem/Onc News and JournalsTweet-
RT @IBCResearch: @OncoAlert #bcsm Another trastuzumab biosimilar on the market! https://t.co/9P8zJqDDst
-
-
Mashup Score: 0
Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.
Source: Center for BiosimilarsCategories: General Medicine Journals and SocietiesTweet-
Dr Michael Wang discusses the importance of #biosimilars in cancer care @MDAndersonNews https://t.co/ecLfSxZ2TS https://t.co/x3C9vKer1g
-
-
Mashup Score: 1Supreme Court to Rule on ACA's Fate After 2020 Election - 4 year(s) ago
The Supreme Court will hear an appeal by a coalition of 20 mainly Democratic states, which are hoping for a reversal of a Fifth Circuit Court of Appeals ruling that held the Affordable Care Act’s (ACA) individual mandate is unconstitutional and called into question whether the remaining provisions of the law could still stand. However, a decision will not come until after the November 2020…
Source: Center for BiosimilarsCategories: General Medicine Journals and SocietiesTweet-
RT @BiosimCenter: Supreme Court to rule on #ACA after #Election2020 https://t.co/wvKUEKITiQ
-
COVID-19 Could Accelerate US Biosimilar Uptake (via @AJMC_Journal @BiosimCenter) https://t.co/3JHPHgcSw8 #COVID19 #coronavirus #biosimilars